gavin
Topics Engaged In
-
- Topic
- Voices
- Posts
- Last Post
-
-
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Pa
Started by:
in: Clinical Trials
- 1
- 1
- 4 years, 9 months ago
-
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With
Started by:
in: Clinical Trials
- 1
- 1
- 4 years, 9 months ago
-
A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previo
Started by:
in: Clinical Trials
- 1
- 1
- 4 years, 9 months ago
-
Predictive Factors and Microbial Spectrum for Infectious Complications after Hep
Started by:
in: Surgery, Resection & Transplant Treatment Options
- 1
- 1
- 4 years, 9 months ago
-
Management implications of fluorodeoxyglucose positron emission tomography/magne
Started by:
in: New Developments
- 1
- 1
- 4 years, 9 months ago
-
PTPN3 suppresses the proliferation and correlates with favorable prognosis of pe
Started by:
in: New Developments
- 1
- 1
- 4 years, 9 months ago
-
A case of small in situ perihilar cholangiocarcinoma incidentally accompanied by
Started by:
in: New Developments
- 1
- 1
- 4 years, 9 months ago
-
Immunotherapy combination is greater than the sum of its parts
Started by:
in: Websites
- 1
- 1
- 4 years, 9 months ago
-
[Surgical treatment of malignant biliary tract diseases
Started by:
in: Surgery, Resection & Transplant Treatment Options
- 1
- 1
- 4 years, 9 months ago
-
Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurr
Started by:
in: New Developments
- 1
- 1
- 4 years, 9 months ago
-
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors Phase II, m
Started by:
in: Clinical Trials
- 1
- 1
- 4 years, 9 months ago
-
STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectini
Started by:
in: Clinical Trials
- 1
- 1
- 4 years, 9 months ago
-
My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erl
Started by:
in: Clinical Trials
- 1
- 1
- 4 years, 9 months ago
-
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Pa